Thalys(SH:603716)2026-01-29 08:40Financial Performance - The company expects a net profit attributable to shareholders for 2025 to be between -160 million RMB and -209 million RMB, indicating a decrease in loss by 49.24 million RMB to 23.97 million RMB year-on-year [4]. - The expected net profit attributable to shareholders after deducting non-recurring gains and losses for 2025 is projected to be between -180 million RMB and -230 million RMB, reflecting an increase in loss by 44.92 million RMB to 94.92 million RMB year-on-year [5]. - The total profit for the previous year (2024) was -148.30 million RMB, with a net profit attributable to shareholders of -209.24 million RMB [7]. Strategic Transformation - The company is undergoing a strategic transformation, leading to a decline in operating revenue due to the transfer of certain subsidiaries and the lack of renewal for some business contracts [8]. - Increased R&D investment in the smart medical field has impacted profits, contributing to the expected losses [9]. Receivables and Asset Assessment - The company is actively working on collecting receivables but has faced extended payment cycles from some clients, leading to credit impairment losses [10]. - There is an ongoing assessment of goodwill, long-term equity investments, and other asset values, with results yet to be determined [11]. - The company has not identified any significant uncertainties that could affect the accuracy of the earnings forecast [12].